Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of deferasirox to preparation of drug for treating sarcopenia disease

A deferasirox, disease technology, applied in the field of medicine, to achieve the effects of inhibiting oxidative stress damage, inhibiting skeletal muscle atrophy, and low toxicity

Inactive Publication Date: 2018-09-14
AFFILIATED HOSPITAL OF JIANGSU UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are currently no relevant reports on reducing iron accumulation to prevent sarcopenia, and there is no report on the iron chelator deferasirox reducing iron accumulation in the treatment of sarcopenia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of deferasirox to preparation of drug for treating sarcopenia disease
  • Application of deferasirox to preparation of drug for treating sarcopenia disease
  • Application of deferasirox to preparation of drug for treating sarcopenia disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Establishment of a cell culture model simulating skeletal muscle trophic deficiency in vivo. The well-cultured C2C12 cells (Shanghai Cell Bank, Chinese Academy of Sciences) were divided into 3 groups, the control group (the culture medium was DMEM (high glucose), containing 10% fetal bovine serum, penicillin 100 μg / mL and streptomycin 100 μg / mL ), serum-free medium group (the medium is DMEM (high glucose), containing penicillin 100 μg / mL and streptomycin 100 μg / mL) and serum-free medium plus deferasirox (DFS) group (the medium is DMEM ( High sugar), containing penicillin 100 μ / mL, streptomycin 100 μg / mL, DFS 10 μmol / L), respectively in 5% CO 2 , cultured in a 37°C incubator, and after 48 hours of intervention, the CCK-8 detection reagent (Dojindo Company of Japan) was used to detect the growth activity of the cells, and the apoptosis kit (Invitrogen Company of the United States) was used to detect the apoptosis of the cells.

[0022] figure 1 The effect of deferasirox...

Embodiment 2

[0024] Establishment of a cell culture model simulating skeletal muscle trophic deficiency in vivo. The well-cultured C2C12 cells were differentiated into mature skeletal muscle cells under the induction of horse serum, and the cells were divided into three groups, the control group (the medium was DMEM (high glucose), containing 10% fetal bovine serum, penicillin 100 μ / mL and Streptomycin 100 μg / mL), serum-free medium group (the medium is DMEM (high glucose), containing penicillin 100 μg / mL and streptomycin 100 μg / mL) and serum-free medium plus deferasirox (DFS ) group (the culture medium is DMEM (high sugar), containing penicillin 100 μg / mL, streptomycin 100 μg / mL, DFS 10 μmol / L), respectively in 5% CO 2 , and cultured in a 37°C incubator. After 72 hours of intervention, 10 fields of view under the microscope were randomly observed and the number of skeletal muscle myotubes was counted using Image-Pro Plus 6.0 software.

[0025] figure 2 It is the effect of deferasirox on...

Embodiment 3

[0027] Establishment of a cell culture model that mimics oxidative damage to skeletal muscle in vivo. The well-cultured C2C12 cells were differentiated into mature skeletal muscle cells under the induction of horse serum, and the cells were divided into three groups, the control group (the medium was DMEM (high glucose), containing 10% fetal bovine serum, penicillin 100 μ / mL and streptomycin 100 μg / mL), tumor necrosis factor-α (TNF-α) group (the culture medium is DMEM (high glucose) containing 10% fetal bovine serum, penicillin 100 μg / mL, streptomycin 100 μg / mL, TNF-α 10 ng / mL) and tumor necrosis factor-α (TNF-α) plus deferasirox (DFS) co-incubation group (the medium is DMEM (high glucose), containing 10% fetal bovine serum, penicillin 100 μ / mL, streptomycin 100 μg / mL, TNF-α 10 ng / mL, DFS 10 μmol / L), after 72 h of intervention, the malondialdehyde (MDA) kit (Shanghai Beyond Company) detected intracellular MDA level; glutathione peroxidase (GSH-Px) kit (Beijing Suolaibao Comp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to novel application of sarcopenia, in particular to application of deferasirox to preparation of a drug for treating the sarcopenia disease, and belongs to the technical field of medical novel application. At present, drugs for treating sarcopenia as a result of an iron accumulation factor are absent at the present clinically. Deferasirox is proved to be capable of remarkably inhibiting skeletal muscle atrophy and oxidative stress injury under a sarcopenia pathology state, and is suitable for developing a prevention drug for the sarcopenia.

Description

technical field [0001] The invention relates to the use of deferasirox, in particular to the use of deferasirox in the preparation of medicines for treating sarcopenia, and belongs to the technical field of medicine. Background technique [0002] The chemical name of deferasirox (also known as defersino, DFS) is 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid, The molecular formula is C21H15N3O4, and the molecular weight is 373.36200. Deerasirox is a novel oral triligandyl iron chelator that binds Fe in a 2:1 ratio 3 + , can effectively reduce the iron load in the body, and is clinically applied to patients with chronic iron accumulation in children with thalassemia over 2 years old and patients with iron accumulation caused by other blood transfusion-dependent diseases. Clinical studies have confirmed that compared with deferoxamine and deferiprone, other iron chelators, deferasirox is safer to use, with higher patient tolerance and better compliance. [0003...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4196A61P21/00
CPCA61K31/4196A61P21/00
Inventor 赵国阳徐又佳王波程千狄东华陈静家
Owner AFFILIATED HOSPITAL OF JIANGSU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com